Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | FERMT2 | Q96AC1 | 1/20 | 0.36 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL14739890 | 0.76 | CCR1 (0.52) | CCR1FERMT2HRH3 | |
| SCHEMBL15923405 | 0.68 | CCR1 (0.84) | CCR1FERMT2HRH3 | |
| SCHEMBL14668240 | 0.68 | CCR1 (0.84) | CCR1FERMT2HRH3 | |
| SCHEMBL15923067 | 0.68 | CCR1 (0.84) | CCR1FERMT2HRH3 | |
| Bromide SCHEMBL901715 | 0.67 | CDK1 (0.47) | CCR1FERMT2 | |
| SCHEMBL19841699 | 0.66 | CCR1 (0.86) | CCR1FERMT2HRH3 | |
| Water SCHEMBL20856749 | 0.66 | CHRM2 (0.39) | ACHE | |
| SCHEMBL7549269 | 0.66 | ABL1 (0.44) | SMN1; SMN2KMT2AUTS2R | |
| SCHEMBL23640948 | 0.64 | CCR1 (0.89) | CCR1ACHEFERMT2HRH3 | |
| SCHEMBL17527102 | 0.64 | CCR1 (0.89) | CCR1KMT2AFERMT2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160058749-A1 | TREATMENTS FOR NEUROPATHY | CHILDRENS MEDICAL CENTER (US) | 2016-03-03 | — | — | US | disclosed |
| US-20160045487-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROPATHY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-02-18 | — | — | US | disclosed |
| WO-2014160811-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROPATHY | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2014-10-02 | — | — | WO | disclosed |
| US-20110086878-A1 | Treatments for Neuropathy | NIH-DEITR | 2011-04-14 | — | — | US | disclosed |
| US-7863295-B2 | Treatments for neuropathy | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2011-01-04 | — | — | US | disclosed |
| EP-2240177-A2 | TREATMENTS FOR NEUROPATHY | Children's Medical Center Corporation (US) | 2010-10-20 | — | — | EP | disclosed |
| WO-2009102570-A2 | TREATMENTS FOR NEUROPATHY | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2009-08-20 | — | — | WO | disclosed |
| US-20090203735-A1 | TREATMENTS FOR NEUROPATHY | NIH-DEITR | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160058749-A1 | TREATMENTS FOR NEUROPATHY | NGF, BDNF, NTRK2 | CCR1 867/4885ACHE 89/4885SMN1; SMN2 38/4885 |
| US-20090203735-A1 | TREATMENTS FOR NEUROPATHY | NGF, BDNF, NTRK2 | CCR1 867/4885ACHE 89/4885SMN1; SMN2 38/4885 |
| US-20160045487-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROPATHY | PMP22, GAP43, NGF | CCR1 968/4885ACHE 143/4885SMN1; SMN2 4/4885 |
| US-20110086878-A1 | Treatments for Neuropathy | NGF, BDNF, NTRK2 | CCR1 867/4885ACHE 89/4885SMN1; SMN2 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.